Replies to post #160557 on Biotech Values

[jq1234]

VRTX: I think they gave up developing HCV on their own after VX809 result in much wider CF population last year, VX661 result this month made it complete. They are an orphan drug company where they have no competition for years to come. They look for a big partner to fund the development of VX135 in HCV. They also look to license out VX509 in RA.

[DewDiligence]

ACHN’s had $201M of cash at 3/31/13:

http://finance.yahoo.com/news/achillion-reports-first-quarter-2013-100000691.html

No 1Q13 CC.